HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by BUTCHER, G. A. Articles by SINDEN, R. E. Search for Related Content PubMed PubMed Citation Articles by BUTCHER, G. A. Articles by SINDEN, R. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATOVAQUONE Related Collections Malaria

PERSISTENCE OF ATOVAQUONE IN HUMAN SERA FOLLOWING TREATMENT: INHIBITION OF P. FALCIPARUM DEVELOPMENT IN VIVO AND IN VITRO

Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone^TM, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively. However, using two biologic assays (mosquito transmission and in vitro asexual stage development), we demonstrate here that sera from volunteers treated with atovaquone/proguanil retained activity against Plasmodium falciparum up to 6 weeks after such treatment. This activity was due to atovaquone, as administration of this drug alone replicated the data obtained with the combination. Most notably, asexual stage development of an atovaquone-resistant strain (NGATV01) of P. falciparum was not inhibited by sera taken after atovaquone treatment. These data indicate that for atovaquone, biologic assays, though not quantitative, are more sensitive than the usual physicochemical assays. Also, persistence of atovaquone in plasma at low concentrations for long periods may increase the risk of resistant parasites arising.

Received April 17, 2002. Accepted for publication August 22, 2002.

Acknowledgments: We thank GlaxoWellcome (now GlaxoSmith-Kline) for the supply of Malarone and atovaquone. We also thank our volunteers who took the drugs and donated sera, and J. Mendoza for keeping us supplied with mosquitoes.

Financial support: Dr. Butcher was supported by GlaxoWellcome (now GlaxoSmithKline).

Reprint requests: Dr. G. Butcher, Department of Biologic Sciences, Imperial College of Science Technology and Medicine, Sir Alexander Fleming Building, Imperial College Road, London SW7 2AZ UK, Telephone: 44-0207-5945381, Fax: 44-0207-5495425, E-mail: g.butcher{at}ic.ac.uk

Authors’ addresses: Dr. G. Butcher, Prof. RE Sinden, Department of Biologic Sciences, Imperial College of Science Technology and Medicine, Sir Alexander Fleming Building, Imperial College Road, London.

This article has been cited by other articles:

				M. E. Polhemus, S. Remich, B. Ogutu, J. Waitumbi, M. Lievens, W. R. Ballou, and D. G. Heppner Jr. Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1493 - 1495. [Abstract] [Full Text] [PDF]

				G. D. Shanks, A. J. Magill, D. O. Freedman, J. S. Keystone, D. J. Bradley, and R. Steffen Drug-Free Holidays: Pre-Travel versus During Travel Malaria Chemoprophylaxis Am J Trop Med Hyg, July 1, 2007; 77(1): 1 - 2. [Abstract] [Full Text] [PDF]

				M. D. Edstein, B. M. Kotecka, K. L. Anderson, D. J. Pombo, D. E. Kyle, K. H. Rieckmann, and M. F. Good Lengthy Antimalarial Activity of Atovaquone in Human Plasma following Atovaquone-Proguanil Administration Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4421 - 4422. [Full Text] [PDF]